Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $50.1652W HIGH $111.86
Volume
520.13 K
Value Traded
141.52 M
Short % Float
6.41%
+0.16%Week
-0.58%1 Month
-5.23%3 Month
+24.23%6 Month
+379.74%5 Year
+1,583.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.54 B
EPS (TTM)
4.22
P/E Ratio
23.75
Ent. Value
5.94 B
Total Shares
65.27 M
Float Shares
63.00 M
Insiders
3.52%
Institutions
116.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LNTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Lantheus Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lantheus Holdings, Inc.
328Total events
9Upcoming
112Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Reimbursement / PricingPost-Market
CMS grants Transitional Pass-Through payment status for PYLARIFY TruVu
PSMA positive lesions in men with prostate cancersource ↗
▲First Patient DosedLNTH-2401Trial
First patient dosed in SPARROW Phase 2/3 registrational trial of LNTH-2401
prostate cancersource ↗
▲FDA ApprovalBRAVNETSAApprovedFDA Decision
FDA grants final approval for BRAVNETSA (lutetium Lu 177 dotatate) for GEP-NETs
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
▲FDA ApprovalTAUKLARIFY™ApprovedFDA Decision
FDA approval of TAUKLARIFY™ (Florquinitau F 18 Injection)
Alzheimer’s Diseasesource ↗
◆PDUFA DateLNTH-2501FiledRegulatory Filing
PDUFA date extended to June 29, 2026 for LNTH-2501 NDA
somatostatin receptor positive neuroendocrine tumors (NETs)source ↗
◆Oral PresentationPresentation
Lantheus to present at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Lantheus to present at William Blair 46th Annual Growth Stock Conference
◆Oral Presentation18F-GP1Presentation
Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study
Acute Deep Vein Thrombosissource ↗
▲Oral PresentationLNTH-2513Presentation
LNTH-2513 PET/CT awarded SNMMI Image of the Year at 2026 Annual Meeting
acute lower-extremity deep vein thrombosissource ↗
▲Full ResultsLNTH-2513Clinical Data
Investigator-initiated trial results for LNTH-2513 in DVT presented at SNMMI 2026
acute lower-extremity deep vein thrombosissource ↗
◆Poster PresentationPresentation
Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment
Prostate Cancersource ↗
◆Hatch Waxman LitigationIP / Competition
30-month stay expiration for PNT2003
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
◆Poster PresentationLNTH-2403Presentation
Poster presentation of Phase 1/2 study of LNTH-2403 in osteosarcoma at ASCO 2026
relapsed/refractory osteosarcomasource ↗
◆Poster PresentationPresentation
Publication-only presentation on real-world use of piflufolastat F 18 in prostate cancer at ASCO 2026
early-stage prostate cancersource ↗
◆PDUFA DateLNTH-2501FiledRegulatory Filing
FDA sets PDUFA date for LNTH-2501 (Ga 68 edotreotide) NDA
somatostatin receptor-positive neuroendocrine tumors (NETs)source ↗
▲FDA ApprovalFDA Decision
FDA approval of PYLARIFY TruVu (piflufolastat F 18) injection
prostate cancersource ↗
◆PDUFA DateRegulatory Filing
PDUFA date set for new formulation of piflufolastat F 18
prostate cancersource ↗
▲Tentative ApprovalFDA Decision
FDA tentative approval for PNT2003
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
▲Tentative ApprovalPNT2003FiledFDA Decision
FDA tentative approval for PNT2003
gastroenteropancreatic neuroendocrine tumors (GEP-NETs)source ↗
◆Poster PresentationFlorbetabenApprovedPresentation
Poster presentation at CTAD 2025: Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab
Alzheimer's diseasesource ↗
◆Management ChangeCorporate
Mary Anne Heino appointed Executive Chairperson effective November 7, 2025
▲FDA Filing AcceptedMK-6240ApprovedRegulatory Filing
FDA accepted NDA for MK-6240
Alzheimer's diseasesource ↗
▲Partnership / LicensePYLARIFYApprovedCorporate
Exclusive licensing agreement with GE HealthCare for Japan
prostate cancersource ↗
◆Oral PresentationPresentation
Lantheus CEO to present at Morgan Stanley 23rd Annual Global Healthcare Conference
▲FDA Filing AcceptedRegulatory Filing
FDA accepted NDA for new formulation of piflufolastat F 18
prostate cancersource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA accepted NDA for new PSMA PET formulation
PSMA PET imagingsource ↗
●Timing GuidanceMK-6240ApprovedPresentation
NDA submission expected in Q3 2025
Alzheimer's diseasesource ↗
◆Oral PresentationLNTH-1363SPresentation
Optimized Production and Quality Control of the FAP imaging Agent [64Cu]LNTH-1363S
FAP imagingsource ↗
◆Poster PresentationLNTH-1363SPresentation
Preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in mouse models of myocardial infarction
FAP PET imaging in myocardial infarctionsource ↗
▲FDA ApprovalNeuraceqApprovedFDA Decision
FDA approval of Neuraceq (florbetaben F18 injection)
Alzheimer's disease (beta-amyloid plaque detection)source ↗
◆Poster PresentationLNTH-1363SPresentation
First Clinical Evaluation of 68Ga-LNTH-1363S, a Novel FAP-Targeting Radiopharmaceutical for PET Imaging: Physiological Biodistribution and Tumor Uptake in Cancer Patients
FAP-targeting PET imagingsource ↗
◆Poster PresentationPYLARIFYApprovedPresentation
18F-Piflufolastat PET/CT in Patients with Biochemically Recurrent Prostate Cancer: a CONDOR Sub-analysis of Positive Predictive Value in the Prostate/Prostatic Bed Stratified by PSA
Biochemically Recurrent Prostate Cancersource ↗
◆Oral PresentationPresentation
Lantheus CEO presentation at 2025 Truist Securities MedTech Conference
◆Oral PresentationPresentation
Lantheus CEO presentation at Goldman Sachs 46th Annual Global Healthcare Conference 2025
Past FDA Catalysts and PDUFA Decisions
How LNTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-13 | MK-6240 | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B64 / 100
Pipeline Score
$4.2B
Pipeline Value
$6.4B
Commercial Value
Not rated
Valuation Signal
9
Drugs Scored
2.1x
rNPV / MCap
Top 5%
Small Cap(rank 34 of 658)
Percentile Rank
Lantheus Holdings, Inc. holds a solid B-grade pipeline (64/100), with $6.5B risk-adjusted pipeline value, led by 18F-DCFPyL in Prostate Cancer (Phase 3), across $82B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.6B x 4.1 = $6.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| PYLARIFY | $962M | $1.0B | -7% |
| DEFINITY | $340M | $326M | +4.2% |
| Neuraceq | $127M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18F-DCFPyL Small moleculeNCT03392181 | Prostate Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 641 | Jun 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every LNTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| 177Lu-PNT2002 Fast Track | metastatic castration-resistant prostate cancer | Phase 3 | 2024-09-15 | radiographic progression free survival: 9.5 months vs. 6.0 months; overall response rate: 38.1% vs. 12.0%; hazard ratio: 0.71; p value: 0.0088; patients halted therapy due to teae: 3.0% vs. 11.5%Read More | Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McHugh JulieDirector | Grant/Award | 4,137 30,099 held | $0.00 | 05/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LNTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.8 % (60 %) | 21.08 M | 190.00 K | 52% ( 65.00 K) |
LNTH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LNTH ranks across every disease it competes in
Competitive Position is a premium feature
See how LNTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLNTH News
LNTHLantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Lantheus Holdings announced that the Centers for Medicare & Medicaid Services has granted Transitional Pass-Through payment status for its PYLARIFY TruVu injection, effective October 1, 2026. This designation allows for separate reimbursement in outpatient settings, enhancing access to innovative diagnostic tools for prostate cancer patients. The company plans a phased rollout to improve supply and reach more patients.
Read more →LNTHLantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Lantheus Holdings has initiated the SPARROW Phase 2/3 trial by dosing the first patient with LNTH-2401, a PET imaging agent targeting the gastrin-releasing peptide receptor in prostate cancer. The trial aims to evaluate the agent's diagnostic performance, safety, and tolerability, with a focus on improving disease characterization. This marks a significant advancement in Lantheus's pipeline for prostate cancer diagnostics.
Read more →LNTHLantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Lantheus Holdings has received final FDA approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a radiopharmaceutical that is bioequivalent and therapeutically equivalent to LUTATHERA®. This approval marks a significant advancement for treating adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company is focused on ensuring reliable supply and broad patient access as they prepare for the product's launch.
Read more →LNTHLantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Lantheus Holdings, Inc. has received FDA approval for TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-labeled PET imaging agent designed for Alzheimer's disease. This approval represents a major milestone in enhancing diagnostic capabilities for clinicians. The company aims to improve patient outcomes through innovative radiopharmaceuticals.
Read more →LNTHLantheus Reports Second Quarter 2026 Financial Results
Lantheus reported its financial results for the second quarter of 2026, revealing worldwide revenue of $388.2 million. The GAAP fully diluted earnings per share were $1.11, slightly down from $1.12 in the same quarter of 2025. Adjusted fully diluted earnings per share also decreased to $1.55 from $1.57 year-over-year.
Read more →LNTHCurium Announces Definitive Agreement to Merge with Lantheus
Curium has entered into a definitive agreement to merge with Lantheus, offering shareholders up to $114.50 per share, which includes a cash payment of $102.50 at closing and potential additional payments tied to performance milestones. This merger aims to create a leading radiopharmaceutical company, enhancing capabilities in oncology, neurology, and cardiology across more than 70 countries. The transaction is expected to close in the first half of 2027, subject to regulatory approvals.
Read more →LNTHLantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has announced a conference call and webcast scheduled for August 6, 2026, at 8:00 a.m. ET. The call will focus on discussing the company's financial results for the second quarter and providing a business update. This event reflects the company's commitment to keeping stakeholders informed.
Read more →LNTHLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
Lantheus received a Complete Response Letter from the FDA for its LNTH-2501 NDA, citing unresolved manufacturing conditions at a third-party facility. The FDA did not raise concerns about the data or the product's safety and efficacy. Lantheus remains committed to resolving the issues and advancing the product.
Read more →LNTHLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Lantheus Holdings, Inc. announced that John Wiggins, Vice President of External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for 8:40 a.m. ET on June 9. The conference participation underscores Lantheus's commitment to improving patient outcomes through their innovative radiopharmaceutical solutions, which the company has provided for 70 years.
Read more →LNTHLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
Lantheus Holdings, Inc. announced that its LNTH-2513 (18F-GP1) PET/CT imaging agent received the Image of the Year award from SNMMI at the 2026 Annual Meeting. This recognition highlights the agent's high diagnostic accuracy in detecting acute lower-extremity deep vein thrombosis (DVT) and its potential to improve thrombus visualization. The study demonstrated impressive sensitivity and specificity rates, along with a well-tolerated safety profile.
Read more →LNTHLantheus to Present at the William Blair 46th Annual Growth Stock Conference
Lantheus Holdings, Inc. announced that John Wiggins, Vice President of External Manufacturing, will speak at the William Blair 46th Annual Growth Stock Conference. The event is scheduled for June 3 at 12:10 p.m. ET. The company, dedicated to radiopharmaceuticals, aims to improve patient outcomes through innovative solutions. A live webcast of the presentation will be available on Lantheus's website, ensuring access for interested parties.
Read more →LNTHLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
Lantheus Holdings, Inc. announced that it will present new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting in Los Angeles. The presentations will cover significant topics, including the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management and the diagnostic performance of 18F-GP1 PET/CT for deep vein thrombosis. These advances aim to improve patient outcomes and demonstrate Lantheus' commitment to innovation in the radiopharmaceutical sector.
Read more →LNTHLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Lantheus Holdings, Inc. announced that it will present data at the 2026 ASCO Annual Meeting. The presentation will include a phase 1/2 study of LNTH-2403, a targeted monoclonal antibody for osteosarcoma. The meeting is scheduled for May 29 to June 2, 2026, in Chicago, IL.
Read more →LNTH▲ +5.6%on this news
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Lantheus Holdings, Inc. reported a strong start to 2026 with revenues of $377.3 million, reflecting a 1.2% increase year-over-year. The company achieved FDA approval for PYLARIFY TruVu and received tentative approval for PNT2003. However, sales of PYLARIFY saw a decline, and operating income decreased significantly. The company reaffirmed its financial guidance for the year.
Read more →LNTHLantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. has scheduled its first quarter 2026 earnings conference call and webcast for May 7, 2026, at 8:00 a.m. ET. This event will focus on discussing the company's financial results and provide an update on business developments. Participants are encouraged to register online in advance to avoid delays. The company has a longstanding reputation in the radiopharmaceutical sector, providing products that enhance patient care.
Read more →LNTHLantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Lantheus Holdings, Inc. announced that the FDA has extended the review period for the New Drug Application of LNTH-2501 (Ga 68 edotreotide) by three months, now targeting June 29, 2026. This extension is due to the FDA's need for additional information related to manufacturing. Importantly, the delay is not associated with safety or efficacy concerns. LNTH-2501 is designed for diagnosing somatostatin receptor-positive neuroendocrine tumors but remains unavailable for sale in the U.S.
Read more →LNTHLantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Lantheus Holdings, Inc. announced FDA approval for PYLARIFY TruVu (piflufolastat F 18) injection, a new formulation of its PSMA PET imaging agent for prostate cancer. The improved formulation aims to enhance diagnostic performance, increase batch sizes, and support broader geographic availability. Expected to launch in the fourth quarter of 2026, PYLARIFY TruVu will provide more significant access to high-quality imaging for men with prostate cancer. The approval was supported by data from pivotal studies OSPREY and CONDOR, ensuring its safety and effectiveness.
Read more →LNTHLantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection | Lantheus Holdings, Inc.
Lantheus announced FDA approval of PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent, enhancing patient access and manufacturing efficiency. The product is expected to launch in Q4 2026, addressing clinician needs for greater diagnostic availability.
Read more →LNTHLantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Lantheus Holdings has received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA, aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks a significant advancement in treatment options for patients. However, full approval is contingent upon the expiration of a 30-month stay related to patent litigation.
Read more →About Lantheus Holdings, Inc.
Headquarters331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862
BIOPHARMAWATCH ELITE PLUS
Trade the next LNTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime